AMTURNIDE
LOE ApproachingNDAORALTABLET
Approved
Dec 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMTURNIDE is an oral tablet small-molecule drug approved by Novartis in December 2010 for an undisclosed indication. The product is currently in the loss-of-exclusivity (LOE) approaching phase of its lifecycle.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely focused on defense strategies and lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AMTURNIDE offers limited career growth opportunities given its LOE-approaching status and lack of linked job postings. This role is best suited for professionals seeking experience in defensive brand management, generic transition, or lifecycle extension strategies.
Brand ManagerProduct Manager
Worked on AMTURNIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.